Literature DB >> 31599954

Discordance in the Epithelial Cell-Dendritic Cell Major Histocompatibility Complex Class II Immunoproteome: Implications for Chlamydia Vaccine Development.

Karuna P Karunakaran1, Hong Yu1, Xiaozhou Jiang1, Queenie W T Chan2, Leonard J Foster2, Raymond M Johnson3, Robert C Brunham1.   

Abstract

BACKGROUND: Chlamydia trachomatis and Chlamydia muridarum are intracellular bacterial pathogens of mucosal epithelial cells. CD4 T cells and major histocompatibility complex (MHC) class II molecules are essential for protective immunity against them. Antigens presented by dendritic cells (DCs) expand naive pathogen-specific T cells (inductive phase), whereas antigens presented by epithelial cells identify infected epithelial cells as targets during the effector phase. We previously showed that DCs infected by C trachomatis or C muridarum present epitopes from a limited spectrum of chlamydial proteins recognized by Chlamydia-specific CD4 T cells from immune mice.
METHODS: We hypothesized that Chlamydia-infected DCs and epithelial cells present overlapping sets of Chlamydia-MHC class II epitopes to link inductive and effector phases to generate protective immunity. We tested that hypothesis by infecting an oviductal epithelial cell line with C muridarum, followed by immunoaffinity isolation and sequencing of MHC class I- and II-bound peptides.
RESULTS: We identified 26 class I-bound and 4 class II-bound Chlamydia-derived peptides from infected epithelial cells. We were surprised to find that none of the epithelial cell class I- and class II-bound chlamydial peptides overlapped with peptides presented by DCs.
CONCLUSIONS: We suggest the discordance between the DC and epithelial cell immunoproteomes has implications for delayed clearance of Chlamydia and design of a Chlamydia vaccine.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Chlamydiazzm321990 ; Bm1.11; MHC class II; T cell; vaccine

Mesh:

Substances:

Year:  2020        PMID: 31599954      PMCID: PMC7457330          DOI: 10.1093/infdis/jiz522

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  IMMUNOLOGY. A Chlamydia vaccine on the horizon.

Authors:  Robert C Brunham
Journal:  Science       Date:  2015-06-19       Impact factor: 47.728

2.  Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine.

Authors:  Karuna P Karunakaran; Hong Yu; Xiaozhou Jiang; Queenie Chan; Kyung-Mee Moon; Leonard J Foster; Robert C Brunham
Journal:  Vaccine       Date:  2015-03-01       Impact factor: 3.641

3.  The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection.

Authors:  H Su; R Morrison; R Messer; W Whitmire; S Hughes; H D Caldwell
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

4.  Prevalence and persistence of asymptomatic Chlamydia trachomatis infections in urine specimens from Danish male military recruits.

Authors:  Adriaan J C van den Brule; Christian Munk; Jeanette F Winther; Susanne Krüger Kjaer; Hans O Jørgensen; Chris J L M Meijer; Servaas A Morré
Journal:  Int J STD AIDS       Date:  2002-12       Impact factor: 1.359

5.  The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up.

Authors:  Servaas A Morré; Adriaan J C van den Brule; Lawrence Rozendaal; A Joan P Boeke; Feja J Voorhorst; Sjoerd de Blok; Chris J L M Meijer
Journal:  Int J STD AIDS       Date:  2002-12       Impact factor: 1.359

6.  Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice.

Authors:  Hong Yu; Karuna P Karunakaran; Xiaozhou Jiang; Robert C Brunham
Journal:  Vaccine       Date:  2014-06-30       Impact factor: 3.641

7.  Chlamydia public health programs and the epidemiology of pelvic inflammatory disease and ectopic pregnancy.

Authors:  Michael L Rekart; Mark Gilbert; Rafael Meza; Paul H Kim; Michael Chang; Deborah M Money; Robert C Brunham
Journal:  J Infect Dis       Date:  2012-10-24       Impact factor: 5.226

8.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

9.  Differential infection outcome of Chlamydia trachomatis in human blood monocytes and monocyte-derived dendritic cells.

Authors:  Baishakhi Datta; Florence Njau; Jessica Thalmann; Hermann Haller; Annette D Wagner
Journal:  BMC Microbiol       Date:  2014-08-14       Impact factor: 3.605

10.  Genomic transcriptional profiling of the developmental cycle of Chlamydia trachomatis.

Authors:  Robert J Belland; Guangming Zhong; Deborah D Crane; Daniel Hogan; Daniel Sturdevant; Jyotika Sharma; Wandy L Beatty; Harlan D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-18       Impact factor: 12.779

View more
  2 in total

1.  A Class II-Restricted CD8γ13 T-Cell Clone Protects During Chlamydia muridarum Genital Tract Infection.

Authors:  Raymond M Johnson; Norma Olivares-Strank; Gang Peng
Journal:  J Infect Dis       Date:  2020-05-11       Impact factor: 5.226

2.  Reverse vaccinology approach towards the in-silico multiepitope vaccine development against SARS-CoV-2.

Authors:  Vipul Kumar; Sudhakar Kancharla; Prachetha Kolli; Manoj Jena
Journal:  F1000Res       Date:  2021-01-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.